Shilpa Medicare’s Hyderabad Facility Gets Europe GMP Certificate

Shilpa Medicare Ltd, a leading pharmaceutical company, has achieved a significant milestone by securing Good Manufacturing Practice (GMP) certification from the European Union (EU). This certification was granted after a thorough inspection of its Unit VII facility in Hyderabad, marking a testament to the company’s commitment to quality standards.

EU GMP Certification Following EMA Inspection

The certification follows an inspection conducted by the European Medicines Agency (EMA), Austria, from September 24 to September 26, at Shilpa Medicare’s Unit VII in Nacharam, Hyderabad. This facility houses an Analytical Services Division (QC) and a Bio-Analytical Department, both of which play critical roles in testing drug substances, raw materials, packaging, and finished products.

Unit VII is already recognised for its excellence, having approvals from the United States Food and Drug Administration (USFDA) and EMA Europe for its Bio-Analytical Laboratory. The recent EMA inspection was the first of its kind by a European agency for the Quality Control laboratory, further strengthening the facility’s global reputation.

Comprehensive Analytical Capabilities

Shilpa Medicare’s Unit VII facility specializes in various analytical activities, including method validations, method transfers, and other analytical studies. Its laboratories are instrumental in ensuring the quality and safety of products released into the US, EU, and other international markets. The EU GMP certification from EMA underscores Shilpa Medicare’s dedication to maintaining international quality standards.

Shilpa Medicare Share Performance

As of December 23, 2024, 1:50 PM, the shares of Shilpa Medicare Ltd. are trading at ₹776.05 per share with a decline of 4.56% from its previous day’s closing price. Over the last month, the stock has seen a decline of 13.50%. While over the year the stock has surged by 118.20% the stock has a 52-week high and 52-week low of ₹959.50 per share and ₹313.15 per share respectively.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.